Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparison of target genes from the pregnane X receptor (Pxr) in the liver vs the intestine [colon]

ABSTRACT: Comparison of target genes from the pregnane X receptor (Pxr) in the liver vs the intestine [colon]

PROVIDER: PRJNA510394 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Comparison of target genes from the pregnane X receptor (Pxr) in the liver vs the intestine [colon]

Project description:We performed a transcriptomic comparison of the Pxr-regulated genes in the liver and intestine (ileum and colon) using microarrays in adult wild-type (WT) vs Pxr-/- C57Bl6/J male mice treated with the rodent specific Pxr ligand pregnenolone 16α-carbonitrile (PCN) (100 mg/kg i.p. once daily for 4 days).

2018-12-18 | GSE123963 | GEO

Comparison of target genes from the pregnane X receptor (Pxr) in the liver vs the intestine [ileum]

2018-12-14 | GSE123803 | GEO

Comparison of target genes from the pregnane X receptor (Pxr) in the liver vs the intestine [liver]

2018-12-14 | GSE123802 | GEO

Comparison of target genes from the pregnane X receptor (Pxr) in the liver vs the intestine

Project description:Comparison of target genes from the pregnane X receptor (Pxr) in the liver vs the intestine

| PRJNA509890 | ENA

Comparison of target genes from the pregnane X receptor (Pxr) in the liver vs the intestine [ileum]

Project description:Comparison of target genes from the pregnane X receptor (Pxr) in the liver vs the intestine [ileum]

| PRJNA509891 | ENA

Comparison of target genes from the pregnane X receptor (Pxr) in the liver vs the intestine [liver]

Project description:Comparison of target genes from the pregnane X receptor (Pxr) in the liver vs the intestine [liver]

| PRJNA509892 | ENA

Pregnane X-receptor (PXR/NR1I2) activity is a hallmark of cancer stem cells and drives post-treatment tumor recurrence in colon cancer

Project description:Post-treatment recurrence remains a major clinical challenge in colorectal cancer (CRC), and increasing evidence suggests that Cancer Stem Cells (CSCs) may mediate this process due to their enhanced resistance to conventional therapeutics. We hypothesized that the Pregnane-X receptor (PXR) may drive the chemoresistance of colorectal CSCs.. shRNA-mediated PXR down-regulation was used to analyze the role of PXR on self-renewal in the colorectal cancer cell Line LS174T. Expression and activity of PXR were quantified under conditions that promote Cancer Stem Cells (CSCs) enrichment. Conversely, CSC characterization was performed in cells enriched along their PXR activity level.

2016-08-01 | E-MTAB-3471 | biostudies-arrayexpress

Pregnane X Receptor (PXR) protects against cisplatin-induced acute kidney injury

Project description:Background: Cisplatin-induced acute kidney injury (CAKI) has been recognized as one of the most serious side effects of cisplatin. Pregnane X receptor (PXR) is a ligand-dependent nuclear receptor and serves as a master regulator of xenobiotic detoxification. Increasing evidence also suggests PXR has many nonxenobiotic functions including the regulation of cell proliferation, inflammatory response and glucose and lipid metabolism. Methods: In this study, we aimed to investigate the role of PXR in cisplatin-induced nephrotoxicity. CAKI model was performed in wild-type or PXR knockout mice. Pregnenolone 16α-carbonitrile (PCN), a mouse PXR specific agonist, was used for PXR activation. The renal function, biochemical, histopathological and molecular alterations were examined in mouse blood, urine or renal tissues. Whole transcriptome analysis was performed by RNA sequencing. Dual-luciferase reporter and chromatin immunoprecipitation (ChIP) assays were applied to determine the regulation of PXR on its target genes. Results: We found that PXR activation significantly attenuated CAKI as reflected by improved renal function, reduced renal tubular apoptosis, ameliorated oxidative and endoplasmic reticulum stress, and suppressed inflammatory factor expression. RNA sequencing analysis revealed that the renoprotective effect of PXR was associated with multiple crucial signaling pathways. In particular, PXR protected against cisplatin-induced AKI by the activation of PI3K/AKT pathway and the induction of multidrug and toxin extrusion 1 (MATE1), an important transporter mediating cellular excretion of cisplatin, in the kidney. Conclusions: Our results demonstrate that PXR activation can preserve renal function in cisplatin-induced AKI and suggest a possibility of PXR as a novel therapeutic target for cisplatin-induced nephrotoxicity.

2023-03-20 | GSE147256 | GEO

B3galt5 regulates obesity and insulin resistance by maintaining the intestinal integrity as a novel PXR target gene

Project description:Pregnane X receptor (PXR), a xenobiotic receptor involved in drug metabolism, has been reported to regulate lipid and glucose metabolism. The intestine tract is the first inner barrier of the body, which dysfunction contributes to the development of metabolic disorders. However, the role of intestinal PXR in metabolic diseases remains largely unknown. In this study, we showed that activation of PXR by tributyl citrate (TBC), an intestinal-selective agonist of PXR, improved high fat diet (HFD)-induced obesity and insulin resistance. The metabolic benefit of intestinal PXR activation was associated with upregulation of β-1,3 galactosyltransferase 5 (B3galt5). Our results revealed that B3galt5 is mainly expressed in the intestine and is a direct transcriptional target of PXR. Whole-body and intestine-specific knockout of B3galt5 exacerbated HFD-induced obesity, insulin resistance and inflammation. Mechanistically, B3galt5 is essential to maintain the integrity of intestinal mucus barrier. Ablation of B3galt5 impaired the O-glycosylation of mucin2, destabilized the mucus layer, and increased the permeability of intestinal barrier. Furthermore, B3galt5 deficiency abolished the beneficial effect of intestinal PXR activation on metabolic disorders. Our results suggested the intestinal-selective activation of PXR regulated B3galt5 expression holds an important role in maintaining metabolic homeostasis, making it a potential therapeutic strategy in obesity.

2024-07-02 | GSE266942 | GEO

B3galt5 regulates obesity and insulin resistance by maintaining the intestinal integrity as a novel PXR target gene [ileum]

2024-07-02 | GSE270696 | GEO